TDCS is a non-invasive form of neurostimulation, in which constant, low current is delivered directly to areas of the brain using small electrodes; ©Maxim Malevich/ panthermedia.net
A new report by Institut de recherches cliniques de Montreal (IRCM) ethics experts raises important questions and concerns about transcranial direct current stimulation (tDCS). Over the past several decades, neurostimulation techniques such as tDCS have gradually gained favor in the public eye.
In a new report IRCM ethics experts raise important questions about the rising tide of tDCS coverage in the media, while regulatory action is lacking and ethical issues need to be addressed.
TDCS is a non-invasive form of neurostimulation, in which constant, low current is delivered directly to areas of the brain using small electrodes. Originally developed to help patients with brain injuries such as strokes, tDCS is now also used to enhance language and mathematical ability, attention span, problem solving, memory, coordination, and even gaming skills. Recently, states the report, tDCS has caused excitement in the lay public and academia as a ''portable, painless, inexpensive and safe'' therapeutic and enhancement device.
"Despite these claims, the effects of tDCS are hard to predict," explains Eric Racine, PhD, Director of the Neuroethics research unit at the IRCM who supervised the research project. "The safety and efficacy of tDCS have only been demonstrated in controlled laboratory settings and, without supervision, the use of tDCS for enhancement might cause serious adverse effects such as temporary respiratory paralysis."
The report shows the amount of publicly-available information on tDCS has increased dramatically in recent years, both in academic literature and print media articles. IRCM researchers analyzed the available information and found a considerable mismatch in tone and focus between academic and print media articles.
While academic articles focused on therapeutic and investigative uses of tDCS, discussions in print media articles mainly concentrated on potential enhancement uses, as well as therapeutic applications. In addition, media discussions have been optimistic, with little information concerning ethical issues, therapeutic limitations, or side effects that could result from widespread use, whereas academic articles usually involved a more balanced discourse.
"We encountered strong and potentially misleading statements about the real-world effects and applications of tDCS in print media headlines," says Veljko Dubljevic, PhD, postdoctoral fellow in the IRCM's Neuroethics research unit and first author of the report. "In our entire sample of media articles, only 3.5 per cent advised caution or mentioned the possibility of adverse effects."
Given the nature of tDCS and the lack of oversight governing its use, the report explains that academic and print media discourse could shape the public's risk-benefit perceptions, impact the uptake of this technology, and, consequently, lead to negative implications for ethical and regulatory oversight.
"With the rapid evolution of tDCS in the public domain and in academia, we recommend three areas of action to tackle the social, ethical and policy implications," adds Dubljevic. "First, to curtail misunderstandings about tDCS, professional societies, researchers and government agencies should work toward increasing neuroscientific literacy by providing objective neutral data to the media and the public. Second, tDCS devices, as well as their marketing and manufacturing standards, need to be monitored and regulated. Training and licensing procedures should also be considered. Finally, we believe that physicians and other clinicians should become actively engaged in the discussion about ethical, clinical and policy aspects of tDCS."
"The current regulatory gap means that tDCS is readily available as a service, product, or even a homemade device, in many countries without any guidance being provided by policy makers," concludes Racine. "A response to the policy and regulatory aspects of tDCS is urgently needed."
MEDICA.de; Source: Institut de recherches cliniques de Montreal